Bliss GVS Pharma Limited (BLISSGVS) — Announcement

📢 Key Event
ICRA assigned A-(Stable)/A2+ rating to ₹100 crore facility for Bliss GVS Pharma.

🔄 What Changed
New rating assigned; surveillance due within 12 months from April 8, 2026; rating subject to review if instrument terms, size, or borrowing limits change

🔮 What's Next
Surveillance review due within one year from rating date; ICRA may revise rating at any time based on new information or changed circumstances

💡 Investor Takeaway
The A- stable rating signals manageable credit risk and validates Bliss GVS Pharma's ability to service debt, supporting confidence in financial stability.

⚠️ Risks
Rating subject to immediate review if company defaults on interest/principal, exceeds borrowing limits, or experiences material adverse changes in debt servicing capability

ICRA Limited assigned a new credit rating of [ICRA]A-(Stable)/[ICRA]A2+ to Bliss GVS Pharma's ₹100 crore fund-based and non-fund-based facilities with Federal Bank Limited on April 8, 2026. The A- stable rating indicates upper-medium credit quality with low default risk. Surveillance review is due within one year, and ICRA reserves the right to revise ratings based on material changes in financial performance or debt terms.

📄 View Original Announcement (PDF)

📊 Stock Analysis — BLISSGVS ✨ Ask AI About This